Screening and Detecting Counterfeit Biologics Drugs

Government health agencies and pharmaceutical manufacturers are finding ways to fight counterfeit and substandard drugs by identifying them from manufacturing, throughout the supply chain, and eventually when they reach the public after they are sold in the retail pharmacies. This whitepaper is co-authored by speaker Ravi Kalyanaraman of Bristol-Myers Squibb.

Please note: That all fields marked with an asterisk (*) are required.

First Name *

Last Name *

Job Title *

Company Name *

Email Address *

Telephone *

Mobile Telephone

Country *

Where did you hear about us?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.